Det nye forumet finner du her

Tilbake til: Farma og medisin
Innlegg av: Hyggelige (03.05.18 19:32 ), lest 320 ganger
Ticker: TRVX

RE^1: Nytt kontor i USA

Preclinical development
A study of the efficacy of the combination of ONCOS-102 and two different doses of
KEYTRUDA® in a melanoma mouse model has been performed showing synergistic antitumor effects of ONCOS-102 and KEYTRUDA®:

- KEYTRUDA® alone at both doses did not reduce tumor volume

- ONCOS-102 reduced tumor volume by 51 percent

- ONCOS-102 + KEYTRUDA® reduced volume by 61 percent (lower dose) and 69 percent (higher dose)

These trial data support the scientific rationale for the ongoing melanoma clinical trial of
ONCOS-102 in combination with KEYTRUDA®